Trials / Completed
CompletedNCT01344889
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,459 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g. Pegasys/peginterferon alfa-2a) and ribavirin. Data will be collected from each patient for the duration of their treatment and for up to 6 months thereafter.
Conditions
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2011-04-29
- Last updated
- 2016-11-02
Locations
260 sites across 25 countries: Albania, Algeria, Bahrain, Belgium, Bosnia and Herzegovina, Brazil, Egypt, Greece, Hungary, India, Iran, Italy, Kuwait, Lebanon, Morocco, North Macedonia, Pakistan, Poland, Portugal, Qatar, Romania, Serbia, Slovakia, South Korea, United Arab Emirates
Source: ClinicalTrials.gov record NCT01344889. Inclusion in this directory is not an endorsement.